CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: Fictions and facts

Virchows Archiv

Volumn 442, Issue 3, 2003, Pages 218-225

  Strater J ^a   Moller P ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

CD95; Colorectal cancer; Inflammatory bowel disease; Ligand; Regeneration

Indexed keywords

FAS ANTIGEN; LIGAND; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; APOPTOSIS; BASOLATERAL MEMBRANE; CROSS LINKING; DIGESTIVE SYSTEM CANCER; ENTERITIS; GASTROINTESTINAL TRACT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; MUCOSA INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 0037355877     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-003-0760-z     Document Type: Review

References (71)

1. Abreu MT, Palladino AA, Arnold ET, Kwon RS, McRoberts JA (2000) Modulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells. Gastroenterology 119:1524-1536
2. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S (1995) Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 11:294-300
3. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71-77
4. Allison J, Georgiou HM, Strasser A, Vaux DL (1997) Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 94:3943-3947
5. Ansari B, Coates PJ, Greenstein B, Hall PA (1993) In situ end labelling (ISEL) detects DNA strand breaks in apoptosis and in other physiological and pathological states. J Pathol 170:1-8
6. Arai H, Gordon D, Nabel EG, Nabel GJ (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 94:13862-13867
7. Baker JR Jr, Bretz JD (2000) Specificity questions concerning the clone 33 anti-fas ligand antibody. Cell Death Differ 7:8-9
8. Bellgrau D, Gold D, Selawry H, Moore H, Franzusoff A, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377:630-632
9. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F (1998) The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160:5669-5675
10. Bennett MW, O'Connell J, O'Sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F (1999) Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 44:156-162
11. Bennett MW, O'Connell J, Houston A, Kelly J, O'Sullivan GC, Collins JK, Shanahan F (2001) Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol 54:598-604
12. Bonhagen K, Thoma S, Bland P, Bregenholt S, Rudolphi A, Claesson MH, Reimann J (1996) Cytotoxic reactivity of gut lamina propria CD4+ alpha beta T cells in SCID mice with colitis. Eur J Immunol 26:3074-3083
13. Bregenholt S, Petersen TR, Claesson MH (2001) The majority of lamina propria CD4 (+) T-cells from scid mice with colitis undergo Fas-mediated apoptosis in vivo. Immunol Lett 78:7-12
14. Dhein J, Walczak H, Bäumler C, Debatin K-M, Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438-441
15. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793-800
16. Eastwood GL (1977) Progress in gastroenterology: gastrointestinal epithelial renewal. Gastroenterology 72:962-975
17. Elkon KB, Liu CC, Gall JG, Trevejo J, Marino MW, Abrahamsen KA, Song X, Zhou JL, Old LJ, Crystal RG, Falck-Pedersen E (1997) Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 94:9814-9819
18. Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B (2000) The tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023-5027
19. Fiedler P, Eibel H (2000) Antibody mAb33 from Transduction Laboratories detects human CD95L in ELISA but not in immunoblots. Cell Death Differ 7:126-128
20. Fiedler P, Schaetzlien CE, Eibel H (1998) Constitutive expression of FasL in thyrocytes. Science 279:2015
21. Fulda S, Debatin KM (2002) IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21:2295-2308
22. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501
23. Giordano C, Stassi G, DeMaria R, Toldaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzo A (1997) Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275:960-963
24. Gitter AH, Wullstein F, Fromm M, Schulzke JD (2001) Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 121:1320-1328
25. Griffith TS, Ferguson TA (1997) The role of FasL-induced apoptosis in immune privilege. Immunol Today 18:240-244
26. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192
27. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schreier P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366
28. Hall PA, Coates PJ, Ansari B, Hopwood D (1994) Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 107:3569-3577
29. Herr I, Posovsky C, Bohler T, Debatin K-M (2000) mAb 33 from Transduction Laboratories specifically binds to human CD95-L. Cell Death Differ 7:129-130
30. Hershberg RM, Framson PE, Cho DH, Lee LY, Kovats S, Beitz J, Blum JS, Nepom GT (1997) Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing. J Clin Invest 100:204-215
31. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, Imada A, Binion DG, Musso A, West GA, Dobrea GM, McCormick TS, Lapetina EG, Levine AD, Ottaway CA, Fiocchi C (1999) Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 163:1081-1090
32. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface Fas can mediate apoptosis. Cell 66:233-243
33. Iwamoto M, Koji T, Makiyama K, Kobayashi N, Nakane PK (1996) Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol 180:152-159
34. Ju ST, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A (1994) Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 91:4185-4189
35. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek D, Stock PG, Baekkeshov S (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3:738-743
36. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579-5588
37. Klas C, Debatin K-M, Jonker RR, Krammer PH (1993) Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 5:625-630
38. Krammer PH (2000) CD95's deadly mission in the immune system. Nature 407:789-795
39. Lau HT, Yu M, Fontana A, Stoeckert CJJ (1996) Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109-112
40. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin K-M, Krammer PH, Möller P (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily. Lab Invest 69:415-429
41. Lowin B, Hahne M, Mattmann C, Tschopp J (1994) Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650-652
42. Mann B, Gratchev A, Böhm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ, Hanski C (1999) FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 79:1262-1269
43. Merger M, Viney JL, Borojevic R, Steele-Norwood D, Zhou P, Clark DA, Riddell R, Maric D, Podack ER, Croitoru K (2002) Defining the roles of perforin, Fas/FasL, and tumor necrosis factor α in T cell induced mucosal damage in the mouse intestine. Gut 51:155-163
44. Möller P, Koretz K, Leithäuser F, Brüderlein S, Henne C, Quentmeier A, Krammer PH (1994) Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57:371-377
45. Möller P, Walczak H, Riedl S, Sträter J, Krammer PH (1996) Paneth cells express high levels of CD95 ligand transcripts. A unique property among gastrointestinal epithelia. Am J Pathol 149:9-13
46. Nagata S, Suda T (1995) Fas and Fas ligand: 1pr and gld mutations. Immunol Today 16:39-43
47. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082
48. O'Connell, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F (1998) Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 186:240-246
49. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richard S, Dhein J, Trauth BC, Ponsting W, Krammer PH (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis/nerve growth factor receptor superfamily. J Biol Chem 267:10709-10715
50. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806-809
51. Reyher U von, Sträter J, Kittstein W, Gschwendt M, Krammer PH, Möller P (1998) Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58:526-534
52. Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D, Wiley SR (1999) IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 163:920-926
53. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94:6420-6425
54. Simpson SJ, De Jong YP, Shah SA, Comiskey M, Wang B, Spielman JA, Podack ER, Mizoguchi E, Bran AK, Terhorst C (1998) Consequences of Fas-ligand and perforin expression by colon T cells in a mouse model of inflammatory bowel disease. Gastroenterology 115:849-855
55. Smith D, Sieg S, Kaplan D (1998) Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 160:4159-4160
56. Stokes TA, Rymaszewski M, Arscott PL, Wang SH, Bretz JD, Bartron J, Baker JrJR (1998) Constitutive expression of FasL in thyrocytes. Science 279:2015
57. Sträter J, Koretz K, Günthert AR, Möller P (1995) In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis. Gut 37:819-825
58. Sträter J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A, Krammer PH, Möller P (1997) CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 113:160-167
59. Sträter J, Mariani SM, Walczak H, Rücker FG, Leithäuser F, Krammer PH, Möller P (1999) CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L. Am J Pathol 154:193-201
60. Sträter J, Walczak H, Hasel C, Melzner I, Leithäuser F, Möller P (2001) CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ 8:273-278
61. Sträter J, Walczak H, Pukrop T, von Müller L, Hasel C, Kornmann M, Mertens T, Möller P (2002) TRAIL and its receptors in the colonic epithelium: a putative role in the defence of viral infections. Gastroenterology 122:659-666
62. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the Tumor Necrosis Factor family (1993) Cell 75:1169-1178
63. Suzuki A, Sugimura K, Ohtsuka K, Hasegawa K, Suzuki K, Ishizuka K, Mochizuki T, Honma T, Narisawa R, Asakura H (2000) Fas/Fas ligand expression and characteristics of primed CD45RO+ T cells in the inflamed mucosa of ulcerative colitis. Scand J Gastroenterol 35:1278-1283
64. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 10:1567-1574
65. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-521
66. Ueyama H, Kiyohara T, Sawara N, Isozaki K, Kitamura S, Kondo S, Miyagawa J, Kanayama S, Shinomura Y, Ishikawa H, Ohtani T, Nezu R, Nagata S, Matsuzawa Y (1998) High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut 43:48-55
67. Walczak H, Krammer PH (2000) The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58-66
68. Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH (1999) Fas/Fas ligand interaction in human colorectal hepatic metastases. Am J Pathol 154:693-703
69. Younes M, Schwartz MR, Finnie D, Younes A (1999) Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Patrol 30:1309-1313
70. Younes M, Schwartz MR, Ertan A, Finnie D, Younes A (2000) Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 88:524-528
71. Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP (1999) Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 162:3273-3279